Short Interest in LAVA Therapeutics (NASDAQ:LVTX) Declines By 20.9%

LAVA Therapeutics (NASDAQ:LVTX) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 45,400 shares, a decline of 20.9% from the August 15th total of 57,400 shares. Based on an average daily volume of 69,300 shares, the short-interest ratio is currently 0.7 days. Currently, 0.3% of the shares of the company are short sold.

Hedge Funds Weigh In On LAVA Therapeutics

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC purchased a new stake in LAVA Therapeutics (NASDAQ:LVTX) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 14,000 shares of the company’s stock, valued at approximately $47,000.

LAVA Therapeutics Stock Up 2.1 %

NASDAQ LVTX opened at $1.72 on Monday. LAVA Therapeutics has a twelve month low of $1.13 and a twelve month high of $6.47. The stock has a market cap of $43.60 million, a PE ratio of -1.59 and a beta of 0.51. The firm has a 50-day simple moving average of $1.86 and a 200 day simple moving average of $2.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.39 and a current ratio of 6.39.

LAVA Therapeutics (NASDAQ:LVTX) last announced its quarterly earnings data on Tuesday, August 20th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative return on equity of 48.53% and a negative net margin of 228.02%. On average, research analysts forecast that LAVA Therapeutics will post -1.28 EPS for the current year.

Wall Street Analysts Forecast Growth

LVTX has been the subject of several recent analyst reports. JMP Securities restated a “market outperform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research note on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research report on Friday, June 28th.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.